Localized Prostate Cancer
Conditions
Brief summary
Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. Men with localized prostate cancer will receive TOOKAD® Soluble VTP under general anesthesia. To evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP in men with prostate cancer Gleason score 7(3+4).
Detailed description
This is a single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. The primary objective of the study is to evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP. Men with Gleason score 7 (3+4) prostate cancer on one half of the prostate will receive TOOKAD® Soluble VTP under general anesthesia. Treatment will consist in hemiablation procedure designed to destroy the lobe of the prostate gland that contains the Gleason score 7 (3+4) cancer. Afterwards, patients will be followed for 5 years (60 months) with clinical evaluation, questionnaires on QOL, erectile and urinary functions, and PSA testing. In addition, treatment outcomes will be assessed based on prostate biopsy results at 3, 12, 24, 36, 48 and 60 months after the TOOKAD® Soluble treatment. All patients will undergo biopsy at 3 and 12 months. If the Month 3 biopsy is positive for any cancer, patients will be allowed a single re-treatment by TOOKAD® Soluble VTP to one or both lobes.
Interventions
DRUGTOOKAD Soluble 4 mg/kg
Vascular targeted photodynamic therapy using TOOKAD Soluble
Sponsors
Steba Biotech S.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men over 18 years of age. 2. Patients who have had a multiparametric MRI of the prostate performed and have undergone transrectal systematic biopsy plus biopsy of any volumes considered suspicious per the MRI (PIRADS version 2 score of 4 or 5) within 6 months before signing consent. 3. Histologic diagnosis of prostate cancer identifying Gleason score of 3+4 on one half of the prostate gland in no more than 2 sextants of the prostate gland and not present in more than 50% of any one core taken systematically. The involvement criterion does not apply to cores taken from MRI suspicious volumes. 4. Patients with concomitant Gleason score 3+3 prostate cancer in less than 50% of any core at any site will be considered eligible. 5. Prostate cancer stage up to cT2a - N0/Nx - M0/Mx. 6. Prostate volume ≥25 mL and ≤70 mL. 7. Serum PSA ≤10 ng/mL. 8. Men who are sexually active with women of childbearing potential must use contraceptive method with a failure rate of less than 1% per year. Contraception should be continued for a period of 90 days after the VTP procedure. The individual methods of contraception may be determined in consultation 9. Signed Informed Consent Form.
Exclusion criteria
1. Unwillingness to accept the treatment; 2. Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy) or chemotherapy; 3. Any surgical intervention for benign prostatic hypertrophy; 4. Any condition or history of illness or surgery that might pose an additional risk to men undergoing the VTP procedure; 5. Life expectancy less than 10 years; 6. Participation in another clinical study involving an investigational product within 1 month before study entry; 7. Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks, especially inability to understand and fulfill the health-related QOL questionnaire; 8. Subjects in custody and or residing in a nursing home or rehabilitation facility; 9. Biopsy proven locally advanced or metastatic prostate cancer. 10. Any condition or history of illness or surgery that in the opinion of the investigator might affect the conduct and results of the study or pose additional risks to the subject (e.g., cardiac or respiratory disease precluding general anesthesia; anticoagulant treatment which cannot be temporarily withdrawn for the procedure). 11. Medical conditions that preclude the use of general anesthesia; 12. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of fistula formation; 13. Hormonal manipulation (excluding 5-alpha-reductase inhibitors) that alters androgen production within the previous 6 months; 14. History of urethral stricture disease; 15. History of acute urinary retention within 6 months of study entry; 16. Condition requiring medication with potential photosensitizing effects (tetracyclines, quinolones, sulphonamides, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics, griseofulvin, and amiodarone) if these treatments could not be stopped at least 10 days before and for 3 days after the VTP procedure or replaced by treatments without photosensitizing properties; 17. Anticoagulant drugs (e.g., warfarin) that could not be withdrawn during the 10 days prior to the VTP procedure or antiplatelet drugs (e.g. aspirin) that could not be withdrawn during the 10 days prior to the VTP procedure and 3 days after VTP; 18. Renal and hepatic disorders with values of \>1.5 times the upper limit of normal (ULN) or blood disorders (upon clinician judgment); 19. A history of sun hypersensitivity or photosensitive dermatitis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participants With Negative Biopsy for Gleason Score 7 (Gleason Grade 4 or 5) Prostate Cancer on 12-month Post-treatment | 12 months | This outcome reports the percent of participants with response to treatment defined as absence of high-grade cancer (Gleason score 7 (Gleason grade 4 or 5) on bilateral biopsy at 12-month post VTP treatment. The Gleason grading system is a histopathological scale used to evaluate the aggressiveness of prostate cancer. The Gleason score is determined by summing the two most predominant histological patterns observed in tumor tissue, each graded on a scale from 1 (well-differentiated) to 5 (poorly differentiated). The total Gleason score ranges from 2 to 10, with higher scores indicating more aggressive disease. PP (per protocol) is all participants who met all key eligibility criteria at baseline and did not have any major deviations that could invalidate eligibility or the integrity/timing of the 12-month biopsy (biopsy missing/out of window, or pre-12-month salvage therapy). ITT( intent-to treat) is all patients who undergo VTP procedure, regardless of protocol deviations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absence of Gleason Score 7 ( Gleason Grade 4 or 5) in Entire Prostate | 3, 12, 24,36,48, 60 months | Binary response to treatment defined as the absence of Gleason score 7 ( Gleason grade 4 or 5 ) biopsy at or before months 3, 12, 24, 36, 48 and 60. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of Gleason grade 4 or 5, the subject will be considered to have responded. |
| Absence of Any Prostate Cancer on Biopsy | months 3, 12, 24, 36, 48 and 60 | Binary response to treatment defined as the absence of any prostate cancer on biopsy on or before months 3, 12, 24, 36 and 60. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of any cancer, the subject will be considered to have responded |
| Absence of Gleason Score 7 (Gleason Grade 4 or 5) in the Treated Lobe | months 3,12, 24, 36, 48 and 60 | Binary response to treatment defined as the absence of Gleason score 7 (Gleason grade 4 or 5) biopsy at or before months 3,12, 24, 36, 48 and 60 in the treated lobe. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of Gleason grade 4 or 5, the subject will be considered to have responded; |
| Absence of Any Prostate Cancer on Biopsy in the Treated Lobe | months 3, 12, 24, 36, 48 and 60 | Binary response to treatment defined as the absence of any prostate cancer on biopsy on or before months 3, 12, 24, 36, 48 and 60 in the treated lobe. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of any cancer, the subject will be considered to have responded |
| Changes in Biopsy Parameters (Gleason Score) | 3,12,24,36,48, 60 months | Changes in biopsy parameters (Gleason score) between the baseline biopsy (Gleason score 7 (3+4) and months 3, 12, 24, 36, 48 , 60 biopsies. The Gleason grading system is a histopathological scale used to assess prostate cancer aggressiveness, with total scores ranging from 2 to 10 (sum of two predominant patterns graded 1-5). Higher scores indicate more aggressive disease. This outcome reports the proportion of participants with absence of high-grade cancer (no Gleason score \<7 (Gleason pattern \< 4 or 5) in the treated lobe at each time point |
| The International Prostate Symptom Score (IPSS) Questionnaire | months 1, 3, 6, 12, 24, 36, 48 and 60 | The International Prostate Symptom Score (IPSS) is a 7 item questionnaire assessing lower urinary tract symptom severity. Each item is scored from 0 to 5, item scores are summed to give a total score ranging from 0 to 35. Higher scores indicate more severe symptoms and a worse outcome. Scores of 0-7 indicate mild, 8-19 moderate and 20-35 severe symptoms. Patient-reported outcome measures (PROMs) impairment: urinary symptoms using IPSS prior to treatment beginning and then 1, 3, 6, 12, 24, 36, 48 and 60 months after completing treatment |
| International Index of Erectile Function (IIEF15) Questionnaire | months 1, 3, 6, 12, 24, 36, 48 and 60 | The International Index of Erectile Function (IIEF 15) is a 15 item questionnaire assessing male sexual function. Item scores are summed to obtain a total score ranging s from 5 to 75. Higher total scores indicate better sexual function and therefore a better outcome. |
| Severe Prostate Cancer Related Events | up to 60 months | Severe prostate cancer-related events defined as cancer extension to T3, metastasis or prostate cancer-related death |
| Secondary Prostate Cancer Treatment | Up to 60 months | Use of secondary prostate cancer treatment following VTP will include surgical removal of the prostate gland, radiation treatment to the prostate gland, use of hormone or chemotherapies |
| PSA | Months 1, 3, 6, 12, 24, 36, 48, 60 | Serum PSA measurements in ng/mL at visit 0 (baseline) and at follow up visits at 1, 3, 6,12,24,36,48 and 60 months. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJonathan Coleman, MD
Memorial Sloan Kettering Cancer Center
Participant flow
Recruitment details
Fifty men presenting with Gleason score 7 (3+4) prostate cancer in at least one lobe were enrolled in the study.
Participants by arm
| Arm | Count |
|---|---|
| TOOKAD Soluble 4 mg/kg TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
TOOKAD Soluble 4 mg/kg: Vascular targeted photodynamic therapy using TOOKAD Soluble | 50 |
| Total | 50 |
Baseline characteristics
| Characteristic | TOOKAD Soluble 4 mg/kg |
|---|---|
| Age, Customized Age | 61.9 years STANDARD_DEVIATION 5.8 |
| Number of Participants with Biopsy for Gleason score 7 (3+4) prostate cancer in at least one lobe | 50 Participants |
| Race/Ethnicity, Customized Race, (%) African American | 1 Participants |
| Race/Ethnicity, Customized Race, (%) American Indian/Alaska Native | 1 Participants |
| Race/Ethnicity, Customized Race, (%) Asian | 1 Participants |
| Race/Ethnicity, Customized Race, (%) Unknown/Not Reported | 8 Participants |
| Race/Ethnicity, Customized Race, (%) White | 39 Participants |
| Region of Enrollment United States | 50 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 50 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 50 |
| other Total, other adverse events | 50 / 50 |
| serious Total, serious adverse events | 9 / 50 |
Outcome results
Primary
Number of Participants With Negative Biopsy for Gleason Grade 4 or 5 Prostate Cancer on 12-month Post-treatment
Binary response to treatment defined as absence of Gleason grade 4 or 5 on biopsy on 12-month post-treatment following TOOKAD® Soluble VTP in men with Gleason score 7 (3+4) prostate cancer
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| TOOKAD Soluble 4 mg/kg | Number of Participants With Negative Biopsy for Gleason Grade 4 or 5 Prostate Cancer on 12-month Post-treatment | 38 participants |
Secondary
Absence of Any Gleason 4 or 5 in the Treated Lobe
Binary response to treatment defined as the absence of any Gleason grade 4 or 5 biopsy on or before months 12, 24, 36, 48 and 60 in the treated lobe. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of gleason grade 4 or 5, the subject will be considered to have responded;
Time frame: months 12, 24, 36, 48 and 60
Secondary
Absence of Any Prostate Cancer on Biopsy
Binary response to treatment defined as the absence of any prostate cancer on biopsy on or before months 3, 12, 24, 36 and 60. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of any cancer, the subject will be considered to have responded;
Time frame: months 3, 12, 24, 36 and 60
Secondary
Absence of Any Prostate Cancer on Biopsy in the Treated Lobe
Binary response to treatment defined as the absence of any prostate cancer on biopsy on or before months 3, 12, 24, 36, 48 and 60 in the treated lobe. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of any cancer, the subject will be considered to have responded
Time frame: months 3, 12, 24, 36, 48 and 60
Secondary
Absence of Gleason Grade 4 or 5
Binary response to treatment defined as the absence of any Gleason grade 4 or 5 biopsy on or before months 24, 36, 48 and 60. If a subject is retreated following a positive biopsy at 3 months and subsequent biopsy shows absence of gleason grade 4 or 5, the subject will be considered to have responded;
Time frame: months 24, 36, 48 and 60
Secondary
Adverse Events
Collection Adverse events
Time frame: Up to 60 months
Secondary
Changes in Biopsy Parameters (Cancer Core Length)
Changes in biopsy parameters (cancer core length) between the baseline biopsy and Month 3, Month12, Month 24, Month 36, Month48 and Month 60 biopsies
Time frame: months 3, 12, 24, 36, 48 and 60
Secondary
Changes in Biopsy Parameters (Gleason Score)
Changes in biopsy parameters (Gleason score) between the baseline biopsy and Month 3, Month12, Month 24, Month 36, Month48 and Month 60 biopsies
Time frame: months 3, 12, 24, 36, 48 and 60
Secondary
Changes in Biopsy Parameters (Number of Positive Score)
Changes in biopsy parameters (number of positive score) between the baseline biopsy and Month 3, Month12, Month 24, Month 36, Month48 and Month 60 biopsies
Time frame: months 3, 12, 24, 36, 48 and 60
Secondary
IIEF15 Questionnaire
Changes in patients' reported outcome measures (PROMs) for erectile function using IIEF 15 (changes in IIEF 15 scores from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months after treatment)
Time frame: months 1, 3, 6, 12, 24, 36, 48 and 60
Secondary
IPSS Questionnaire
Changes in patients' reported outcome measures (PROMs) for urinary symptoms using IPSS (changes in IPSS scores from baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months after treatment)
Time frame: months 1, 3, 6, 12, 24, 36, 48 and 60
Secondary
PSA
Serum PSA measurements in ng/mL.
Time frame: Months 1, 3, 6, 12, 24, 36, 48, 60
Secondary
Secondary Prostate Cancer Treatment
Use of secondary prostate cancer treatment following VTP will include surgical removal of the prostate gland, radiation treatment to the prostate gland, use of hormone or chemotherapies
Time frame: Up to 60 months
Secondary
Severe Prostate Cancer-related Events
Severe prostate cancer-related events: cancer extension to T3, metastasis or prostate cancer-related death
Time frame: Up to 60 months